Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 238

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Neoadjuvant chemoradiotherapy plus surgery versus active surveillance for oesophageal cancer: a stepped-wedge cluster randomised trial

Open access
on behalf of the SANO-study group, Noordman, Bo Jan, Wijnhoven, Bas P. L., Lagarde, Sjoerd M., Boonstra, Jurjen J., Coene, Peter Paul L. O., Dekker, Jan Willem T., Doukas, Michael, van der Gaast, Ate, Heisterkamp, Joos, Kouwenhoven, Ewout A., Nieuwenhuijzen, Grard A. P., Pierie, Jean-Pierre E. N., Rosman, Camiel, van Sandick, Johanna W., van der Sangen, Maurice J. C., Sosef, Meindert N., Spaander, Manon C. W., Valkema, Roelf, van der Zaag, Edwin S., Steyerberg, Ewout W., van Lanschot, J. Jan B. · 2018 · BMC Cancer

Abstract

Background: Neoadjuvant chemoradiotherapy (nCRT) plus surgery is a standard treatment for locally advanced oesophageal cancer. With this treatment, 29% of patients have a pathologically complete response in the resection specimen. This provides the rationale for investigating an active surveillance approach. The aim of this study is to assess the (cost-)effectiveness of active surveillance vs. standard oesophagectomy after nCRT for oesophageal cancer. Methods: This is a phase-III multi-centre, stepped-wedge cluster randomised controlled trial. A total of 300 patients with clinically complete response (cCR, i.e. no local or disseminated disease proven by histology) after nCRT will be randomised to show non-inferiority of active surveillance to standard oesophagectomy (non-inferiority margin 15%, intra-correlation coefficient 0.02, power 80%, 2-sided α 0.05, 12% drop-out). Patients will undergo a first clinical response evaluation (CRE-I) 4–6 weeks after nCRT, consisting of endoscopy with bite-on-bite biopsies of the primary tumour site and other suspected lesions. Clinically complete responders will undergo a second CRE (CRE-II), 6–8 weeks after CRE-I. CRE-II will include 18F–FDG-PET-CT, followed by endoscopy with bite-on-bite biopsies and ultra-endosonography plus fine needle aspiration of suspected lymph nodes and/or PET- positive lesions. Patients with cCR at CRE-II will be assigned to oesophagectomy (first phase) or active surveillance (second phase of the study). The duration of the first phase is determined randomly over the 12 centres, i.e., stepped-wedge cluster design. Patients in the active surveillance arm will undergo diagnostic evaluations similar to CRE-II at 6/9/12/16/20/24/30/36/48 and 60 months after nCRT. In this arm, oesophagectomy will be offered only to patients in whom locoregional regrowth is highly suspected or proven, without distant dissemination. The main study parameter is overall survival; secondary endpoints include percentage of patients who do not undergo surgery, quality of life, clinical irresectability (cT4b) rate, radical resection rate, postoperative complications, progression-free survival, distant dissemination rate, and cost-effectiveness. We hypothesise that active surveillance leads to non-inferior survival, improved quality of life and a reduction in costs, compared to standard oesophagectomy. Discussion: If active surveillance and surgery as needed after nCRT leads to non-inferior survival compared to standard oesophagectomy, this organ-sparing approach can be implemented as a standard of care.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12885-018-4034-1

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 238

Metadata

Authors
on behalf of the SANO-study group, Noordman, B. J., Wijnhoven, B. P. L., Lagarde, S. M., Boonstra, J. J., Coene, P. P. L. O., Dekker, J. W. T., Doukas, M., van der Gaast, A., Heisterkamp, J., Kouwenhoven, E. A., Nieuwenhuijzen, G. A. P., Pierie, J.-P. E. N., Rosman, C., van Sandick, J. W., van der Sangen, M. J. C., Sosef, M. N., Spaander, M. C. W., Valkema, R., van der Zaag, E. S., Steyerberg, E. W., & van Lanschot, J. J. B.
Venue
BMC Cancer
Published
2018-02-06
Volume
18
Issue
1
Pages
142-142
ISSN
1471-2407 (ISSN-L)
OpenAlex
W2788485956
Cited by
238
References
5
FWCI
25.69
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Neoadjuvant chemoradiotherapy plus surgery versus active surveillance for oesophageal cancer: a stepped-wedge cluster randomised trial. https://app.cochat.ai/papers/10.1186/s12885-018-4034-1
The paper
on behalf of the SANO-study group, Noordman, B. J., Wijnhoven, B. P. L., Lagarde, S. M., Boonstra, J. J., Coene, P. P. L. O., Dekker, J. W. T., Doukas, M., van der Gaast, A., Heisterkamp, J., Kouwenhoven, E. A., Nieuwenhuijzen, G. A. P., Pierie, J.-P. E. N., Rosman, C., van Sandick, J. W., van der Sangen, M. J. C., Sosef, M. N., Spaander, M. C. W., Valkema, R., . . . van Lanschot, J. J. B. (2018). Neoadjuvant chemoradiotherapy plus surgery versus active surveillance for oesophageal cancer: a stepped-wedge cluster randomised trial. BMC Cancer. https://doi.org/10.1186/s12885-018-4034-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.